Charta raises $55M Series B and expands AI chart-review products for health plans
Charta has raised $55M in Series B funding, with Insight Partners participating, to accelerate AI development and expand into new specialties. The company also announced an expanded suite of chart-review products for health plans.
- Raised
- $55M
- Round
- Series B
- Investor
- 1
- Investors
- Insight Partners
- Target market
- Healthcare providers and health plans
- Use of funds
- Accelerate AI development for greater accuracy and insight for provider teams and expand into new specialties
Get started
Create a free account to read the full story.
Quick Answers
What is the latest news about Charta?
Charta has raised $55M in Series B funding, with Insight Partners participating, to accelerate AI development and expand into new specialties. The company also announced an expanded suite of chart-review products for health plans.
What does Charta do?
Charta develops AI tools for healthcare providers and payers to review medical charts, check coding and documentation accuracy, and identify quality care gaps. Its technology uses large language models to interpret unstructured medical records.
How much did Charta raise?
Charta raised $55M in its Series B.
Who invested in Charta?
Investors named in this Series B include Insight Partners.
How will Charta use the funding?
Charta plans to use the money for accelerate AI development for greater accuracy and insight for provider teams and expand into new specialties.
Where is Charta based?
Charta is based in USA.
Who are the key people at Charta?
Key people named in this report: Justin Liu (Co-founder & CEO) and Scott Morris (Co-founder & CTO).